ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff as set forth in the attached announcement.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

Attachment



EN
27/08/2024

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Morten Larsen
  • Peter Sehested
9h / 5m 9h / 5m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Positive resultater fører peanut-tablet videre til fase II-udvikling

Positive resultater fører peanut-tablet videre til fase II-udvikling ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart modtage deres første doser. Studiet ventes afsluttet i 2026. ALK (ALKB:DC / OMX: ALK B) har i dag annonceret positive interim-resultater fra det kliniske fase I/II studie (navngivet 'ALLIANCE') med sin sublinguale tabletvaccine ('SLIT') til behandling af peanutallergi. Denne del af studiet, som involverede cirka 30 patiente...

11h / 15m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Positive results advance peanut tablet to phase II development

Positive results advance peanut tablet to phase II development ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involved approximately 30 patients, inv...

11h / 15m 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ACARIZAX® godkendt i Europa til behandling af yngre børn

ACARIZAX® godkendt i Europa til behandling af yngre børn ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet godkendt af sundhedsmyndighederne i 21 EU-lande via en type II variationsprocedure. De første lanceringer, blandt andet på ALK's største marked, Tyskland, forventes at finde sted over de kommende måneder.  Godkendelsen er baseret på data fra det største pædiatriske fase 3 AIT-studie (MT-12) med 1.458 børn i Nordamerika og Europa. MT-12-studiet...

December 12, 2024 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ACARIZAX® approved in Europe for treatment of young children

ACARIZAX® approved in Europe for treatment of young children ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-...

December 12, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch